Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 | P05023 | 14/20 | 0.33 |
| ▸ | ATP1B1 | P05026 | 14/20 | 0.33 |
| ▸ | ATP1A3 | P13637 | 14/20 | 0.33 |
| ▸ | ATP1B2 | P14415 | 14/20 | 0.33 |
| ▸ | ATP1A2 | P50993 | 14/20 | 0.33 |
| ▸ | ATP1B3 | P54709 | 14/20 | 0.33 |
| ▸ | FXYD2 | P54710 | 14/20 | 0.33 |
| ▸ | ATP1A4 | Q13733 | 14/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3053035 | 0.79 | ATP1A1 (0.36) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL11810987 | 0.78 | ALDH1A1 (0.32) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL9840935 | 0.75 | ALDH1A1 (0.33) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL27651849 | 0.75 | — | — | |
| SCHEMBL11813555 | 0.75 | CYP2C19 (0.40) | ALDH1A1 | |
| SCHEMBL8922242 | 0.71 | ATP1A1 (0.39) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL758775 | 0.71 | — | — | |
| SCHEMBL28195917 | 0.71 | CYP1A2 (0.39) | — | |
| SCHEMBL22209073 | 0.70 | ALDH1A1 (0.42) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL19888973 | 0.69 | GABRP (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178509-B2 | Method to treat sickle cell disease | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178509-B2 | Method to treat sickle cell disease | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-20080027022-A1 | METHOD TO TREAT GASTRIC LESIONS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-01-31 | — | — | US | disclosed |
| US-20080027022-A1 | METHOD TO TREAT GASTRIC LESIONS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-01-31 | — | — | US | disclosed |
| US-20080009460-A1 | METHOD TO TREAT SICKLE CELL DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-01-10 | — | — | US | disclosed |
| US-20080009460-A1 | METHOD TO TREAT SICKLE CELL DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009460-A1 | METHOD TO TREAT SICKLE CELL DISEASE | PDE4A, ADORA2A, PDE4B | ATP1A1 1195/4885ATP1B1 1431/4885ATP1A3 1157/4885 |
| US-20080027022-A1 | METHOD TO TREAT GASTRIC LESIONS | ADORA2A, ADORA2B, PDE4A | ATP1A1 1514/4885ATP1B1 1744/4885ATP1A3 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.